Variable | Value | Distribution | Source |
---|---|---|---|
Demographic | |||
Malaria prevalence in HIV-infected pregnant women | 31.0% | Beta(3.1,6.9) | [46] |
CD4 count | 390 | Normal(390,220) | [47] |
Incidence | |||
Relative risk of malaria in HIV-infected pregnant woman | 1.6 | Gamma(1.6,1) | [48] |
CD4 change while on ART | 70 | Normal(70,100) | [49] |
Mortality | |||
Neonatal mortality risk due to low birth weight | 6.93% | Beta(0.007,0.093) | [30] |
Annual mortality due to malaria during pregnancy | 0.33% | Beta(0.033,9.967) | [30] |
Annual mortality due to anaemia in pregnancy | 1.0% | Beta(0.1,9.9) | [30] |
Annual HIV mortality among HIV-infected pregnant women | 0.0161% | Beta(0.16,9.84) | [50] |
Annual HIV mortality among HIV-infected pregnant women on ART | 0.007% | Beta(0.07,9.93) | |
Relative risk of HIV mortality of CTX while on ART | 0.47 | Beta(8,9) | [35] |
DALY calculations | |||
Annual discount rate | 3% | 3% | [51] |
Average age (years) | 22.83 | 22.83 | [29] |
Life expectancy for women aged 20–24 (years) | 47.24 | Normal(47,3) | [32] |
Life expectancy at birth (years) | 57.96 | Normal(58,3) | [32] |
Disability weight—malaria during pregnancy | 0.21 | Normal(0.21,0.03) | [31] |
Disability weight—maternal anaemia due to malaria | 0.06 | Normal(0.06,0.02) | [31] |
Disability weight—low birth weight | 0.11 | 0.11 | [33] |
Length of disability (years)—malaria during pregnancy | 0.01 | Gamma(2.0,0.004) | [30] |
Length of disability (years)—maternal anaemia due to malaria | 0.06 | Gamma(1.2,0.04) | [52] |
Length of disability (years)—low birth weight | 57.96 | Gamma(32,1.8) | [32] |
Costs (USD 2015) | |||
Drug cost | |||
Intermittent preventive treatment (per dose) | $0.20 | Normal(0.2,0.01) | |
Cotrimoxazole, 480 mg twice daily (per year) | $6.28 | Gamma(3.9,1.61) | [54] |
Healthcare labor costa | |||
Labor time per IPTp-SP administration (min) | 8.31 | Gamma(13.85,0.6) | [30] |
Nurses’ monthly cost of labor | 542.76 | Gamma(29.3,18.5) | [30] |
Household cost | |||
Antenatal care visit direct cost | 0.47 | Gamma(92.4,0.005) | [30] |
Antenatal care visit indirect cost | 1.17 | Gamma(146,0.008) | [30] |
ART treatment (per year) | $193.61 | Gamma(2,97) | [55] |
Efficacy | |||
Low birth weight | |||
Relative risk baseline (IPTp-SP 0–1 dose) vs. 2 dose IPTp-SP | 3.25 | Gamma(1.1,2.95) | [45] |
Incidence per 1000 women given IPTp-SP 2 dosesb | 175 | (91–222)a | [29] |
Relative risk IPTp-SP 3 doses vs. 2 doses | 0.86 | Normal(0.86,0.21) | [29] |
Relative risk CTX vs. 2 dose IPTp-SP | 1.16 | Gamma (1.05,1.1) | |
Maternal parasitaemia | |||
Relative risk baseline (IPTp-SP 0–1 dose) vs. 2 dose IPTp-SP | 1.4 | Gamma(1.15,1.2) | [19] |
Incidence per 1000 women given IPTp-SP 2 dosesb | 112 | (0–359)a | [29] |
Relative risk IPTp-SP 3 doses vs. 2 doses | 0.26 | Normal(0.26,0.08) | [29] |
Relative risk CTX vs. 2 dose IPTp-SP | 0.44 | Lognormal(−1.05,0.7) | |
Relative risk CTX + ART vs. CTX | 0.38 | Lognormal(−1.2,0.7) | [21] |
Anaemia | |||
Relative risk baseline (IPTp-SP 0–1 dose) vs. 2 dose IPTp-SP | 1.03 | Gamma(0.85,1.2) | [45] |
Incidence per 1000 women given IPTp-SP 2 dosesb | 582 | (333–795)a | [29] |
Relative risk IPTp-SP 3 doses vs. 2 doses | 582 | Normal(0.96,0.07) | [29] |
Relative risk CTX vs. 2 dose IPTp-SP | 0.72 | Normal(0.72,0.05) | [19] |